# A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

> **NCT06500702** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 84 (estimated)

## Conditions studied

- Focal Segmental Glomerulosclerosis
- Glomerulonephritis Minimal Lesion

## Interventions

- **DRUG:** frexalimab
- **DRUG:** brivekimig
- **DRUG:** rilzabrutinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06500702
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2026-12-23
- **Final completion:** 2028-02-16
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500702, "A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06500702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*